Use of a sodium-glucose cotransporter 2, or SGLT2, inhibitor combined with calorie restriction resulted in greater rates of type 2 diabetes remission compared with calorie restriction alone, according ...
With studies showing potential for SGLT2 inhibitors in heart failure ... Others were concerned that there was uncertainty about the mechanism. Cost was also a concern raised by cautious ...
Unfortunately while strides forward have been made in improving survival in heart failure with reduced ejection fraction (HFrEF) – including with AstraZeneca's SGLT2 inhibitor Farxiga/Forxiga ...
use of SGLT2 inhibitors (especially in combination with RAAS inhibitors) can break this “vicious cycle” and provide cardio–renal protection. Insulin resistance is a prevalent pathological mechanism ...
In lupus nephritis(LN), the researchers treated NZB/W lupus mice with a selective histone deacetylase 6 (HDAC6) inhibitor for 4 weeks and showed ... SGLT belongs to the SLC5 gene family. SGLT1 and ...
SGLT2 inhibitors confer greater risk reductions for major adverse cardiovascular events in older adults with type 2 diabetes ...
“Our data suggest SGLT2 inhibition as a safe strategy to prevent kidney stone recurrence in patients with kidney stones ,” Dr Fuster’s team concluded. Other study findings indicate the empagliflozin ...
A recent review shows who newer medications for type 2 diabetes may help the most, particularly in reducing the risk of ...
GLP-1 receptor agonists were more cardioprotective in younger people, but reduced HbA1c more with age. The age of type 2 ...
We read with interest the article by Marie Lund and colleagues published in The Lancet Oncology investigating the association ...
SGLT2 inhibitors are a new family of agents, which occlude the path of SGLT2 glucose reabsorption and cause glucosuria. Efficacy of SGLT2 inhibitors includes reduction of HbA1c, fasting and ...
A national study seeking more effective treatment for deadly metaplastic breast cancer has identified two inhibitor drugs with the potential to interrupt disease progression.